91,097 Shares in Precigen, Inc. $PGEN Acquired by The Manufacturers Life Insurance Company

Posted by Brenda Bartman on Sep 7th, 2026

The Manufacturers Life Insurance Company purchased a new stake in Precigen, Inc. (NASDAQ:PGEN – Free Report) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 91,097 shares of the biotechnology company’s stock, valued at approximately $519,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. KBC Group NV purchased a new stake in shares of Precigen during the 1st quarter worth approximately $1,338,000. Alpine Woods Capital Investors LLC purchased a new position in shares of Precigen in the 2nd quarter valued at $1,309,000. Patient Capital Management LLC purchased a new position in shares of Precigen in the 2nd quarter valued at $108,511,000. Occam Crest Management LP raised its stake in Precigen by 29.6% during the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock worth $14,637,000 after acquiring an additional 799,339 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Precigen during the 1st quarter worth $1,531,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Stock Performance

Shares of PGEN stock opened at $7.10 on Monday. The stock’s 50-day moving average price is $6.20 and its 200 day moving average price is $4.83. The company has a quick ratio of 3.89, a current ratio of 4.58 and a debt-to-equity ratio of 2.15. The stock has a market capitalization of $2.53 billion, a PE ratio of -6.83 and a beta of 1.02. Precigen, Inc. has a 52-week low of $2.99 and a 52-week high of $7.72.

Precigen (NASDAQ:PGEN – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The company had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. The firm’s revenue was up 6322.7% compared to the same quarter last year. As a group, equities research analysts forecast that Precigen, Inc. will post 0.25 EPS for the current year.

Analyst Upgrades and Downgrades

PGEN has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Precigen from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Zacks Research upgraded Precigen from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 5th. Citizens Jmp boosted their target price on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. Finally, Citigroup restated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.50.

Check Out Our Latest Stock Report on Precigen

Insider Buying and Selling

In other Precigen news, COO Rutul R. Shah sold 15,342 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $7.50, for a total transaction of $115,065.00. Following the completion of the transaction, the chief operating officer owned 468,865 shares in the company, valued at approximately $3,516,487.50. This represents a 3.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey B. Kindler sold 185,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the sale, the director owned 17,100 shares of the company’s stock, valued at $127,224. This trade represents a 91.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 991,271 shares of company stock worth $6,208,620 over the last three months. 41.40% of the stock is owned by company insiders.

About Precigen

(Free Report)

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.